Periodic Reporting for period 1 - aortoseal (A minimally invasive and durable endograft fastening solution for Abdominal Aortic Aneurysm (AAA))
Reporting period: 2023-02-01 to 2024-01-31
AAA is a focal enlargement of the abdominal aorta below the renal arteries and is found in up to 4 million patients globally each year. If left untreated it can lead to aneurysm rupture and be fatal in a few hours. It is therefore imperative to provide early, prophylactic treatment of AAA before a rupture occurs. However, the two current leading treatments have major weaknesses. Open surgery is a durable, life-long solution, but can only be performed on low-risk patients (22% of patients). The alternative, EVAR (78%), is minimally invasive with lower immediate risks, but is a much shorter-term solution. EVAR patients require constant monitoring through CT scans (which expose the patient to radiation) to check for graft migration and endoleak. When these inevitably occur, the patient must undergo further interventions which raise costs, add risk, and reduce long-term patient survival.
A solution is greatly needed that combines the long-term durability of open surgery with the low risk, minimal invasiveness of EVAR.
A solution is greatly needed that combines the long-term durability of open surgery with the low risk, minimal invasiveness of EVAR.
Endoron has successfully developed its inaugural product, Aortoseal, designed to seal and secure a stent graft to the aortic wall, ensuring long-term procedural success for Abdominal Aortic Aneurysm (AAA) treatments. The technology patent is granted in the USA and Japan, with expansion into additional global territories, including the EU. The company has initiated First-in-Human (FIH) studies and is establishing research sites across various European countries as well as in the US.
The Endoron Solution, Aortoseal, an endo-sealing Device, is an innovative fixation device based on an intravascular self-stapling (“suture-like”) mechanism to treat AAA EVAR patients. Aortoseal is the only solution for treatment of AAA that combines the long-term durability of a hand sewn suture, with the minimal invasiveness of EVAR. Today, 22% of all cases are recommended to have open surgery to treat their AAA. With Endoron Solution patients can avoid open surgeries which are very risky with higher mortality rates.